PA
EWTX icon

Perceptive Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Perceptive Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-500,000
Closed -$11M – 94
2025
Q1 		$11M Buy
+500,000
New +$13.1M 0.39% 49

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors's EWTX Position: Q1 2026 in Review

Perceptive Advisors reduced its Edgewise Therapeutics (EWTX) stake by 0.76% in Q1 2026, selling an estimated $980K and leaving 4,423,974 shares worth $139M. The position accounts for 2.72% of the portfolio, ranked #9.

Perceptive Advisors first reported a position in EWTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $144M in Q1 2025. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Perceptive Advisors held 4,423,974 shares of Edgewise Therapeutics worth $139M as of Q1 2026.
  • Perceptive Advisors sold 34,000 Edgewise Therapeutics shares in Q1 2026, an estimated $980K.
  • Edgewise Therapeutics made up 2.72% of Perceptive Advisors's portfolio in Q1 2026, its #9 holding.
  • Perceptive Advisors first reported a position in Edgewise Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Perceptive Advisors's Edgewise Therapeutics position peaked at $144M in Q1 2025.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.